When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Marika Taylor currently receives funding from EPSRC, STFC, UK government deparments and the European Horizon programme. In 1980, Stephen Hawking gave his first lecture as Lucasian Professor at the ...

In 1980, Stephen Hawking gave his first lecture as Lucasian Professor at the University of Cambridge. The lecture was called "Is the end in sight for theoretical physics?" Forty-five years later, ...

College students are being wrongly accused of using AI to cheat on their assignments by their university — based, in a headache-inducing twist, on the findings of another AI system. A student named ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...

As you’ve probably heard, if not also experienced, AI is reshaping how we work. If you happen to be a senior professional with sufficient reputational capital, status, and a deep social network, you ...

Our research contributes to debates about the role of Universal Grammar constraints and crosslinguistic influence in sequential bilingual acquisition and use. We investigate experimentally how adult ...

A new drug usually starts with a tragedy. Peter Ray knows that. Born in what is now Zimbabwe, the child of a mechanic and a radiology technician, Ray fled with his family to South Africa during the ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...